Characteristic changes in coronary artery at the early hyperglycaemic stage in a rat type 2 diabetes model and the effects of pravastatin

British Journal of Pharmacology

Volumn 158, Issue 2, 2009, Pages 621-632

  Kajikuri, J ^a   Watanabe, Y ^a   Ito, Y ^a   Ito, R ^a   Yamamoto, T ^a   Itoh, T ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Coronary artery; Endothelial nitric oxide synthase; Endothelium derived hyperpolarizing factor; Endothelium derived nitric oxide; Hyperglycaemia; Pravastatin; Superoxide; Type 2 diabetes

Indexed keywords

9,11 EPITHIO 11,12 METHANOTHROMBOXANE A2; ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; APAMIN; CHARYBDOTOXIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM ION; PRAVASTATIN; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HYPERPOLARIZATION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; ISOMETRICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MUSCLE RELAXATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER MEMBRANE POTENTIAL; WESTERN BLOTTING;

ANIMALS; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; MALE; NITRIC OXIDE SYNTHASE TYPE III; PRAVASTATIN; RATS; RATS, INBRED OLETF; RATS, LONG-EVANS; SUPEROXIDES;

EID: 69549095957     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00348.x     Document Type: Article

References (50)

1. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S et al. (2000). Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101 : 1780 1784.
2. Bayraktutan U, Draper N, Lang D, Shah AM (1998). Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res 38 : 256 262.
3. Bonow RO, Bohannon N, Hazzard W (1996). Risk stratification in coronary artery disease and special populations. Am J Med 101 : 4A17S 22S discussion 22S-24S.
4. 4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res 65 : 823 831.
5. Cash D, Beech JS, Rayne RC, Bath PM, Meldrum BS, Williams SC (2001). Neuroprotective effect of aminoguanidine on transient focal ischaemia in the rat brain. Brain Res 905 : 91 103.
6. Chen Y, Ohmori K, Mizukawa M, Yoshida J, Zeng Y, Zhang L et al. (2007). Differential impact of atorvastatin versus pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 71 : 144 152.
7. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM (2000). Endothelial dysfunction in diabetes. Br J Pharmacol 130 : 963 974.
8. Félétou M, Vanhoutte PM (2000). Endothelium-dependent hyperpolarization of vascular smooth muscle cells. Acta Pharmacol Sin 21 : 1 18.
9. Fleming I, Busse R (2003). Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284 : R1 R12.
10. Förstermann U, Münzel T (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113 : 1708 1714.
11. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. (2001). Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 : 357 362.
12. Garland CJ, Plane F, Kemp BK, Cocks TM (1995). Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci 16 : 23 30.
13. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 : 1141 1148.
14. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al. (2002). Prognostic value of coronary vascular endothelial dysfunction. Circulation 106 : 653 658.
15. Harrison DG (1997). Endothelial function and oxidant stress. Clin Cardiol 20 : II-11 II-17.
16. 2+ mobilization and tension in arterial smooth muscle of the rabbit. J Physiol 457 : 297 314.
17. Itoh T, Kajikuri J, Tada T, Suzuki Y, Mabuchi Y (2003). Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol 548 : 893 906.
18. Jesmin S, Sakuma I, Hattori Y, Fujii S, Kitabatake A (2002). Long-acting calcium channel blocker benidipine suppresses expression of angiogenic growth factors and prevents cardiac remodelling in a Type II diabetic rat model. Diabetologia 45 : 402 415.
19. Kagota S, Yamaguchi Y, Nakamura K, Kunitomo M (2000). Altered endothelium-dependent responsiveness in the aortas and renal arteries of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of non-insulin-dependent diabetes mellitus. Gen Pharmacol 34 : 201 209.
20. Kannel WB, McGee DL (1979). Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2 : 120 126.
21. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T (1992). Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41 : 1422 1428.
22. Kikuchi C, Kajikuri J, Watanabe Y, Itoh T (2008). Effect of chronic administration of pravastatin on enhanced vascular superoxide production in a type 2 diabetes rat model. Nagoya Med J 49 : 95 110.
23. Kim YK, Lee MS, Son SM, Kim IJ, Lee WS, Rhim BY et al. (2002). Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51 : 522 527.
24. Kugiyama K, Ohgushi M, Motoyama T, Sugiyama S, Ogawa H, Yoshimura M et al. (1997). Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 30 : 920 926.
25. Kusama N, Kajikuri J, Watanabe Y, Suzuki Y, Katsuya H, Itoh T (2005a). Characteristics of attenuated endothelium-dependent relaxation seen in rabbit intrapulmonary vein following chronic nitroglycerine administration. Br J Pharmacol 145 : 193 202.
26. Kusama N, Kajikuri J, Yamamoto T, Watanabe Y, Suzuki Y, Katsuya H et al. (2005b). Reduced hyperpolarization in endothelial cells of rabbit aortic valve following chronic nitroglycerine administration. Br J Pharmacol 146 : 487 497.
27. Laufs U, Liao JK (1998). Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 : 24266 24271.
28. Marchenko SM, Sage SO (1996). Calcium-activated potassium channels in the endothelium of intact rat aorta. J Physiol 492 : 53 60.
29. Mata-Greenwood E, Jenkins C, Farrow KN, Konduri GG, Russell JA, Lakshminrusimha S et al. (2006). eNOS function is developmentally regulated: uncoupling of eNOS occurs postnatally. Am J Physiol Lung Cell Mol Physiol 290 : L232 L241.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 : 412 419.
31. Minami A, Ishimura N, Harada N, Sakamoto S, Niwa Y, Nakaya Y (2002). Exercise training improves acetylcholine-induced endothelium-dependent hyperpolarization in type 2 diabetic rats, Otsuka Long-Evans Tokushima fatty rats. Atherosclerosis 162 : 85 92.
32. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T et al. (2006). Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 : 1155 1163.
33. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y et al. (2001). Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci 69 : 1709 1715.
34. Nickenig G, Murphy TJ (1996). Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells. Mol Pharmacol 50 : 743 751.
35. 1-receptor expression. Am J Physiol 272 : H2701 2707.
36. Prior JO, Quiñones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW et al. (2005). Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111 : 2291 2298.
37. Pyorälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G (1997). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 : 614 620.
38. Quiñones MJ, Hernandez-Pampaloni M, Schelbert H, Bulnes-Enriquez I, Jimenez X, Hernandez G et al. (2004). Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 140 : 700 708.
39. Quyyumi AA (1998). Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 105 : 32S 39S.
40. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK et al. (1996). Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97 : 1916 1923.
41. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A et al. (2002). Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105 : 1424 1428.
42. Sakamoto S, Minami K, Niwa Y, Ohnaka M, Nakaya Y, Mizuno A et al. (1998). Effect of exercise training and food restriction on endothelium-dependent relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM. Diabetes 47 : 82 86.
43. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 : 1301 1307.
44. Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, Inoue N et al. (2007). A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol 27 : 1632 1637.
45. Vásquez-Vivar J, Kalyanaraman B, Martásek P, Hogg N, Masters BS, Karoui H et al. (1998). Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95 : 9220 9225. (Pubitemid 28506212)
46. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M (2000). Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 : 61 69.
47. Watanabe Y, Kusama N, Itoh T (2008). Effects of chronic in vivo administration of nitroglycerine on ACh-induced endothelium-dependent relaxation in rabbit cerebral arteries. Br J Pharmacol 153 : 132 139.
48. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273 : 25804 25808.
49. Yamamoto T, Kajikuri J, Watanabe Y, Suzuki Y, Suzumori K, Itoh T (2005). Chronic nitroglycerine administration reduces endothelial nitric oxide production in rabbit mesenteric resistance artery. Br J Pharmacol 146 : 534 542.
50. Yu Y, Ohmori K, Chen Y, Sato C, Kiyomoto H, Shinomiya K et al. (2004). Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 44 : 904 913.